Post by icemandios on Sept 8, 2022 16:56:21 GMT
PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors
PR Newswire
SALT LAKE CITY , Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer , PhD, has decided to resign from its Board of Directors, effective immediately.
"On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague , Chief Executive Officer of PolarityTE. "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we pursued the path that led to an IND accepted by FDA for our product SkinTE® and the start of an approved clinical trial in diabetic foot ulcers."
Dr. Dyer stated, "It has been an honor to serve as a director of PolarityTE. Richard and his team have done an incredible job advancing PolarityTE's IND application and clinical trial process. Now that PolarityTE has settled into a well-defined regulatory path and clinical trial process for SkinTE®, I believe my time and talents may be better applied in other opportunities and endeavors." Dr. Dyer went on to say, "I want to thank my fellow directors and wish the Company nothing but success."
About PolarityTE®
PolarityTE, Inc., headquartered in Salt Lake City, Utah , is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA). SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com .
PR Newswire
SALT LAKE CITY , Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer , PhD, has decided to resign from its Board of Directors, effective immediately.
"On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague , Chief Executive Officer of PolarityTE. "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we pursued the path that led to an IND accepted by FDA for our product SkinTE® and the start of an approved clinical trial in diabetic foot ulcers."
Dr. Dyer stated, "It has been an honor to serve as a director of PolarityTE. Richard and his team have done an incredible job advancing PolarityTE's IND application and clinical trial process. Now that PolarityTE has settled into a well-defined regulatory path and clinical trial process for SkinTE®, I believe my time and talents may be better applied in other opportunities and endeavors." Dr. Dyer went on to say, "I want to thank my fellow directors and wish the Company nothing but success."
About PolarityTE®
PolarityTE, Inc., headquartered in Salt Lake City, Utah , is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA). SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com .